At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 184 enrolled
Drug / intervention
1 drop of 0.375% SYL040012 (bamosiran) +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
In Brief
A Phase 2 clinical trial evaluating 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), and 3 other interventions for Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 184 participants across 21 sites in 4 countries.
Detailed Summary
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28 treatment days in patients with elevated intraocular pressure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen Angle Glaucoma, Ocular Hypertension
CountriesEstonia, Germany, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartOct 2014
Primary CompletionAug 2015
Study CompletionJan 2016
TodayJul 2026
First PostedSep 26, 2014
Enrollment StartOct 1, 2014
Primary CompletionAug 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.8 years ago
Interventions
1 drop of 0.375% SYL040012 (bamosiran)drug
1 drop of 0.750% SYL040012 (bamosiran)drug
1 drop of 1.125% SYL040012 (bamosiran)drug
1 drop of 1.5% SYL040012 (bamosiran)drug
1 drop of 0.5 % timolol maleatedrug